ArticleTherapeutic advances in medical oncology2025
Treatment de-escalation for metastatic good-risk seminoma with carboplatin AUC10: predictive factors and patterns of relapse.
Article in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical Outcomes of the Alternative GAMMA Regimen in Relapsed Germ Cell Tumours.Cancer medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: We have previously demonstrated that carboplatin AUC10 is a viable alternative to cisplatin-based combination chemotherapy for patients with metastatic good-risk seminoma. The International Germ Cell Cancer Collaborative Group (IGCCCG) update identified lactate dehydrogenase (LDH) as an adverse prognostic marker in those receiving cisplatin-based therapies but its relevance in patients treated with carboplatin AUC10 is unknown. Objectives: To update survival outcomes of patients treated with carboplatin AUC10, explore patterns of treatment relapse and determine the impact of clinical and biochemical factors on oncological outcomes. Design: Multi-centre retrospective cohort study of 236 patients treated with carboplatin AUC10 from January 2000 to December 2021. Methods: Clinical parameters including age, stage, number of cycles delivered, primary tumour location, LDH level, relapse date, post-relapse treatment and cause of death were extracted. Progression-free survival (PFS) and overall survival (OS) were estimated using Kaplan-Meier method and event-time distributions were compared using the log-rank test. Variables predictive of PFS and OS were identified using Cox proportional hazards model. Results: The primary tumour site was testis in 95% (n = 225) of patients. Stage distribution was II (86%, n = 204) and III (14%, n = 32). Fourteen patients (6%) relapsed with 11 receiving salvage bleomycin, etoposide and cisplatin. Updated 5-year PFS and OS were 89% and 93%, respectively, over a median follow-up of 88 months. Twenty-three patients (10%) had LDH ⩾2.5 upper limit normal, with 5-year PFS and OS of 78% and 86%, respectively. Age was not associated with risk of relapse. The addition of a fourth cycle of carboplatin was not associated with better outcomes even after adjusting for other risk factors on multivariate analysis. Approximately 50% of relapsed patients were successfully salvaged. Conclusion: Carboplatin AUC10 remains an effective de-escalation regimen for metastatic seminoma, with robust survival rates at prolonged follow-up. Elevated LDH indicates poorer oncological outcomes with carboplatin AUC10, though survival remained comparable to cisplatin-based chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.